Vetter Pharma-Fertigung

What Vetter Pharma-Fertigung does

Vetter Pharma-Fertigung GmbH & Co. KG is a family-owned German Contract Development and Manufacturing Organization (CDMO) headquartered in Ravensburg, Germany, specializing in aseptic fill-and-finish services for injectable drugs. Founded in 1950 and operating for over 76 years, the company delivers a vertically integrated portfolio spanning drug product development, aseptic filling, visual inspection, device assembly, secondary packaging, analytical services, regulatory support, and logistics — covering the full product lifecycle from clinical development through commercial supply. Vetter primarily serves pharmaceutical and biotechnology enterprises producing biologics, monoclonal antibodies, vaccines, and advanced therapy medicinal products, with proprietary technical platforms including the V-OVS® next tamper-evident Luer Lock syringe closure system and V-CRT® cleanroom technology that combines isolator-grade sterility assurance with RABS operational flexibility.

Name

Vetter Pharma-Fertigung

Legal name

Vetter Pharma-Fertigung GmbH & Co. KG

Website

https://vetter-pharma.com

Company type

Private

Founded year

1950

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Vetter Pharma-Fertigung is a family-owned German CDMO specializing in aseptic fill-and-finish services for injectable drugs. It serves global pharmaceutical and biotechnology enterprises with end-to-end capabilities from clinical development through commercialization across facilities in Germany, Austria, and the USA.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Aseptic fill-finish
• Contract manufacturing services
• Injectable drug development
• Pharmaceutical CDMO
• Sterile packaging solutions

Headquarters

HQ city

Ravensburg

HQ country

Germany

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Infrastructure, Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Vetter operates as a CDMO providing comprehensive fill-and-finish services including drug product development, aseptic filling, visual inspection, device assembly, packaging, analytical services, regulatory support, and logistics. Revenue is generated through long-term contract manufacturing agreements with pharmaceutical and biotech companies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Vetter Pharma-Fertigung is a global Contract Development and Manufacturing Organization (CDMO) specializing in aseptic fill-and-finish services for injectable drugs. The company provides end-to-end integrated services including drug product development, aseptic filling, visual inspection, device assembly, packaging, analytical testing, regulatory support, and logistics for pharmaceutical and biotechnology clients from clinical stages through commercial manufacturing.

Product overview

Vetter Pharma-Fertigung is a leading global Contract Development and Manufacturing Organization (CDMO) providing comprehensive fill-and-finish services for injectable drugs. The company operates as a single-source, integrated CDMO offering a portfolio of interconnected services: Drug Product Development (primary packaging evaluation, process design, method transfer, product development), Aseptic Filling & Visual Inspection (clinical and commercial manufacturing with life cycle management), Device Assembly & Packaging (injection device options, secondary packaging, labeling, serialization), Analytical Services (material and product testing, stability studies), Regulatory Support (CMC compliance), and Logistic Services (API storage through dispatch). Key proprietary offerings include V-OVS® next (tamper-evident syringe closure system) and V-CRT® (cleanroom technology). The company also offers specialized programs like Production Excellence (ProdEx) and maintains strategic partnerships such as the Xpert Alliance with Rentschler Biopharma. Services span from clinical development through commercialization, supporting customers from early-phase development to market supply.

Differentiator

Problem solved

Functional benefit

Brands

• V-OVS® next: A new standard for Luer Lock syringe closure systems, a tamper-evident syringe closure system.
• V-CRT®
• Xpert Alliance

Products and services

• Drug Product Development Comprehensive drug product development services including primary packaging evaluation, process design and tech transfer, method transfer, and product development and design to establish scalability, quality, and sustainable value for pharmaceutical and biotechnology clients.
• Aseptic Filling & Visual Inspection Aseptic filling and visual inspection services spanning clinical manufacturing through commercial-scale filling, providing life cycle management support from early development to commercialization for injectable drugs.
• Device Assembly & Packaging Secondary packaging and injection device assembly services including assembly process, devices and components, packaging, and labeling and serialization to differentiate products and improve user experience.
• Analytical Services Comprehensive analytical testing including material testing, product testing, and stability storage and testing to rigorously evaluate and verify product quality from raw materials to release-ready batches.
• Regulatory Support CMC specialists provide regulatory compliance support at every step from clinical development through market authorization and beyond, with expertise across FDA, EMA, and PMDA requirements.
• Logistic Services End-to-end logistics support from API storage through ready-to-dispatch product delivery, including expert logistic consulting, inbound/outbound logistics management, and fully automated warehouse facilities.
• V-OVS® next A tamper-evident syringe closure system for Luer Lock syringes that sets a new standard for safety and user convenience in sterile injectable preparations, available for clients requiring enhanced closure integrity for injectable drug products.

Quantifiable outcome

• 13% revenue growth to €1.26 billion in 2025
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered major, flagship and core.

• MoonLake ImmunotherapeuticsmajorStrategic or Co-development Partner · 21 June 2026Manufacturing partnership with Vetter Pharma International GmbH for commercialization support of sonelokimab, an investigational biologic therapy for moderate-to-severe hidradenitis suppurativa. Vetter will support the drug's manufacturing as MoonLake prepares for FDA Biologics License Application submission.
• Rentschler BiopharmaflagshipStrategic or Co-development Partner · 29 March 2022Strategic alliance strengthened through the Xpert Alliance initiative, combining expertise in biopharmaceutical manufacturing. The collaboration provides integrated solutions from development through market authorization, leveraging complementary capabilities in cell line development, bioprocessing, and aseptic fill-finish.
• SyntegoncoreTechnology or Integration · 5 October 2021Collaborative innovation in small batch filling technology. The partnership received the PDA Drug Delivery Innovation Award 2021 for breakthrough solutions in pharmaceutical manufacturing. Joint development of equipment and processes for high-quality aseptic filling of small batches.

Scale indicators11 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• Lonza Group: One of the world's largest CDMOs offering integrated drug substance (biologics, small molecule APIs) and drug product services. Competitor in aseptic fill-finish but with significantly broader portfolio including cell and gene therapies.
• WuXi Biologics: Global biologics CDMO offering end-to-end services from cell line development to commercial manufacturing and fill-finish. Increasingly competing with Vetter for biologics fill-finish contracts, especially with biotech customers.
• Samsung Biologics: Large-scale biologics CDMO with growing aseptic fill-finish capacity and integrated drug substance plus drug product offering. Competes for commercial-stage biologics manufacturing contracts that overlap with Vetter's customer base.
• Thermo Fisher Scientific (CDMO Services): Through its Patheon CDMO business, offers integrated drug substance and fill-finish services globally. Competes with Vetter particularly for integrated sterile injectable contracts and clinical-to-commercial supply.

Direct peers

• Rentschler Biopharma: German CDMO specializing in biologics manufacturing (microbial and mammalian). Vetter's strategic alliance partner via Xpert Alliance, but also a competitor in biopharmaceutical contract manufacturing services.
• Recipharm: European-headquartered CDMO with significant sterile injectable fill-finish capacity and integrated development services. Direct competitor in aseptic manufacturing for injectable drugs, particularly in Europe.
• Aenova Group: German-headquartered CDMO offering solid, semi-solid, and sterile liquid dosage forms. Direct competitor in the European aseptic fill-finish market with overlapping pharmaceutical customer base.
• Siegfried Holding: Swiss-headquartered CDMO with both API and sterile fill-finish capabilities. Competes with Vetter in aseptic manufacturing services for injectables, especially for European pharmaceutical customers.
• Catalent: Global CDMO with leading aseptic fill-finish and softgel capabilities serving pharmaceutical and biotech customers. Closest direct competitor to Vetter in sterile injectable manufacturing, including pre-filled syringes and vials.

Others

• West Pharmaceutical Services: Supplier of primary packaging components (elastomeric stoppers, plungers, syringe components) used in injectable drug delivery. Adjacent ecosystem partner to Vetter in prefilled syringe and injectable device manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/c/VetterPharma
• Facebookfacebook.com/VetterPharma
• LinkedInlinkedin.com/company/vetter-pharma
• Instagraminstagram.com/vetter_pharma
• TikToktiktok.com/@vetter_pharma
• Xx.com/vetterpharma

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vetter Pharma-Fertigung